Ascendis Pharma A/S - American Depositary Shares (ASND)
Frequently Asked Questions About Ascendis Pharma A/S - American Depositary Shares (ASND)
Does Ascendis Pharma have collaborations with other companies?
Yes, Ascendis Pharma engages in strategic collaborations with other biotechnology and pharmaceutical companies, academic institutions, and healthcare organizations. These partnerships facilitate the sharing of knowledge, resources, and technology, enhancing the company's research capabilities and product development processes.
Has Ascendis Pharma received FDA approval for its products?
As of my last update, TransCon Growth Hormone received FDA approval in 2021 for the treatment of pediatric patients with growth hormone deficiency. This marked a significant milestone for Ascendis Pharma, validating its innovative approach to drug development and enhancing its credibility in the biotechnology sector.
How does Ascendis Pharma engage with investors?
Ascendis Pharma actively engages with investors by providing regular updates on its clinical progress, business developments, and financial performance. The company hosts investor conferences, earnings calls, and other events to communicate its vision and strategies, fostering transparency and trust within the investment community.
How does Ascendis Pharma ensure regulatory compliance?
Ascendis Pharma maintains rigorous regulatory compliance through actions aligning with the guidelines set by regulatory bodies like the FDA and EMA. This involves conducting thorough clinical trials, comprehensive documentation, and soliciting continuous feedback from regulatory agencies to ensure that all products meet safety and efficacy standards.
How does Ascendis Pharma prioritize patient needs?
Ascendis Pharma prioritizes patient needs by focusing on developing therapies for rare and underserved diseases, conducting thorough market assessments, and actively engaging with patient communities. The company places a strong emphasis on understanding and addressing the unique challenges faced by patients, aiming to create meaningful solutions.
Is Ascendis Pharma publicly traded?
Yes, Ascendis Pharma A/S is publicly traded on the Nasdaq stock exchange under the ticker symbol ASND. This listing allows the company to attract investment to fund its research and development initiatives while also providing liquidity for its shareholders.
What are some key products in Ascendis Pharma's pipeline?
Ascendis Pharma has several key product candidates in its pipeline, including TransCon Growth Hormone (TransCon GH), which is being developed for pediatric growth hormone deficiency, and TransCon PTH for hypoparathyroidism. The company is also exploring other therapeutic areas, including endocrine disorders and muscle-wasting diseases.
What are the company's long-term goals?
Ascendis Pharma's long-term goals include building a robust portfolio of innovative therapies that address significant health challenges, achieving global market access for its products, and fostering sustainable growth. The company aims to enhance its position as a leader in biotechnology, ultimately improving patient outcomes worldwide.
What are the potential future developments for Ascendis Pharma?
The potential future developments for Ascendis Pharma include advancing its clinical pipeline, launching new drug candidates, and expanding its therapeutic focus areas. The company is committed to innovation and may explore additional therapeutic areas where its technology can bring significant benefits to patients.
What distinguishes Ascendis Pharma from its competitors?
Ascendis Pharma is distinguished by its proprietary TransCon technology, which allows for the creation of innovative therapies that can improve patient experiences and therapeutic outcomes. Its focus on rare diseases, combined with a commitment to scientific excellence and innovative drug delivery systems, sets it apart in the biotechnology landscape.
What does Ascendis Pharma A/S do?
Ascendis Pharma A/S is a biotechnology company specializing in developing transformative therapies for patients with serious unmet medical needs. The company focuses on advancing its proprietary TransCon technology platform to create unique drug candidates that aim to improve the delivery and efficacy of therapeutic proteins and hormones.
What is Ascendis Pharma's approach to research and development?
Ascendis Pharma employs a rigorous and innovative research and development approach, combining advanced technology platforms with strategic partnerships and collaborations. This methodology is designed to streamline the drug development process and enhance the potential for bringing new therapies to market efficiently.
What is the company's vision?
Ascendis Pharma's vision is to transform the lives of patients with rare and serious diseases by providing innovative therapeutic solutions. The company strives to lead in the development of new therapies that can significantly enhance the quality of life for patients and improve treatment outcomes.
What is the TransCon technology platform?
The TransCon technology platform is a proprietary approach developed by Ascendis Pharma to improve the pharmacokinetics and pharmacodynamics of therapeutic proteins. This technology enables the creation of innovative treatments, facilitating controlled release and prolonged action of the active drug in the body, potentially improving patient outcomes.
What therapeutic areas does Ascendis Pharma focus on?
Ascendis Pharma focuses on developing therapies primarily for rare diseases and endocrine disorders. The company aims to address significant unmet medical needs in these areas through its innovative drug delivery technologies and targeted therapies.
When was Ascendis Pharma A/S founded?
Ascendis Pharma A/S was founded in 2006. Since its inception, the company has been dedicated to innovating and developing therapeutic solutions that address pressing health issues, primarily focusing on rare diseases and significant health challenges.
Where can I find more information about Ascendis Pharma?
More information about Ascendis Pharma can be found on its official website, where the company provides details about its products, pipeline, financial performance, and corporate news. Additionally, investor relations resources, press releases, and clinical trial updates are available for those looking to deepen their understanding of the company.
Where is Ascendis Pharma A/S headquartered?
Ascendis Pharma A/S is headquartered in Copenhagen, Denmark. The company also has a significant presence in the United States, particularly in California, where it conducts a substantial amount of its clinical research and development activities.
Who are the key executives at Ascendis Pharma?
The leadership team at Ascendis Pharma includes experienced professionals from various sectors of biotechnology and pharmaceuticals. Notable executives include the CEO, who has extensive experience in the industry, along with a team of experts overseeing research, development, and commercial strategies.
What is the current price of Ascendis Pharma A/S - American Depositary Shares?
The current price of Ascendis Pharma A/S - American Depositary Shares is 150.09
When was Ascendis Pharma A/S - American Depositary Shares last traded?
The last trade of Ascendis Pharma A/S - American Depositary Shares was at 4:00 pm EDT on April 3rd, 2025
What is the market capitalization of Ascendis Pharma A/S - American Depositary Shares?
The market capitalization of Ascendis Pharma A/S - American Depositary Shares is 8.58B
How many shares of Ascendis Pharma A/S - American Depositary Shares are outstanding?
Ascendis Pharma A/S - American Depositary Shares has 57.15M shares outstanding.